Department of Health System Research, Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University (M.C), Tehran, Iran.
J Gastrointestin Liver Dis. 2009 Dec;18(4):413-8.
BACKGROUND: The prevalence of irritable bowel syndrome (IBS) is relatively high, but up to now, no population based study in Iran has used the ROME III criteria. The aim of the present study was to determine the prevalence of IBS by using the ROME III criteria in the adult population of Iran. METHODS: A face to face survey was conducted in a large area of the Tehran province. IBS was diagnosed by using a validated questionnaire based on the ROME III criteria. RESULTS: The study population comprised 18,180 participants, with a female to male ratio of 1. 15.3% of participants complained of gastrointestinal (GI) symptoms, while the prevalence of IBS was estimated to be 1.1% (139 women, 59 men, p=0.000). IBS patients were more likely to be married, and older. The most common presenting symptoms of IBS were abdominal pain that was relieved by defecation (94%), change in fecal consistency (78%), and change in bowel frequency (70%). Constipation was predominant in 52% of IBS cases, diarrhea was predominant in 18%, and 8% experienced intermittent diarrhea and constipation. CONCLUSION: The prevalence of IBS is relatively low in the Iranian adult population according to the ROME III criteria. The most probable reasons are the specificity of ROME III criteria and the characteristic low prevalence of GI symptoms in the study population.
背景:肠易激综合征(IBS)的患病率相对较高,但迄今为止,伊朗还没有一项基于人群的研究使用过 ROME III 标准。本研究的目的是使用 ROME III 标准在伊朗成年人中确定 IBS 的患病率。
方法:在德黑兰省的一个大区域进行了面对面的调查。通过基于 ROME III 标准的验证问卷诊断 IBS。
结果:研究人群包括 18180 名参与者,女性与男性的比例为 1.15:1。15.3%的参与者抱怨有胃肠道(GI)症状,而 IBS 的患病率估计为 1.1%(139 名女性,59 名男性,p=0.000)。IBS 患者更有可能已婚且年龄更大。IBS 患者最常见的症状是腹痛排便后缓解(94%)、粪便稠度改变(78%)和排便频率改变(70%)。便秘在 52%的 IBS 病例中占主导地位,腹泻在 18%中占主导地位,8%的病例间歇性腹泻和便秘。
结论:根据 ROME III 标准,伊朗成年人中 IBS 的患病率相对较低。最可能的原因是 ROME III 标准的特异性和研究人群中胃肠道症状的特征性低患病率。
J Gastrointestin Liver Dis. 2009-12
J Gastroenterol Hepatol. 2012-4
Eur J Intern Med. 2010-7-14
Aliment Pharmacol Ther. 2007-9-15
Aliment Pharmacol Ther. 2004-8-1
Eur J Gastroenterol Hepatol. 2009-2
Clin Gastroenterol Hepatol. 2009-1
J Gastroenterol Hepatol. 2006-11
Public Health Nutr. 2021-9
Nat Rev Gastroenterol Hepatol. 2020-4-15